docetaxel anhydrous has been researched along with Kidney Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baş, E; Nazıroğlu, M | 1 |
| Dosaka-Akita, H; Honma, R; Iseki, K; Kasashi, K; Kinoshita, I; Kobayashi, M; Saito, Y; Shimizu, Y; Takeuchi, S; Yamada, T | 1 |
| Baudrin, L; Belmont, L; Cadranel, J; Danel, S; Epaud, C; Gounant, V; Lavolé, A; Milleron, B; Rosencher, L; Ruppert, AM | 1 |
| Anagnostopoulos, A; Athanassiades, P; Deliveliotis, C; Dimopoulos, C; Dimopoulos, MA; Mitropoulos, D; Moulopoulos, LA; Papadimitriou, C | 1 |
| Clarke, SJ; Rivory, LP | 1 |
1 review(s) available for docetaxel anhydrous and Kidney Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Child; Clinical Trials as Topic; Docetaxel; Drug Interactions; Forecasting; Humans; Kidney Diseases; Liver Diseases; Paclitaxel; Protein Binding; Taxoids | 1999 |
1 trial(s) available for docetaxel anhydrous and Kidney Diseases
| Article | Year |
|---|---|
Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Kidney Diseases; Male; Middle Aged; Paclitaxel; Taxoids | 1998 |
3 other study(ies) available for docetaxel anhydrous and Kidney Diseases
| Article | Year |
|---|---|
Treatment with melatonin and selenium attenuates docetaxel-induced apoptosis and oxidative injury in kidney and testes of mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Disease Models, Animal; Docetaxel; Drug Therapy, Combination; Humans; Kidney; Kidney Diseases; Male; Melatonin; Mice; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Selenium; Testicular Diseases; Testis; Treatment Outcome | 2019 |
Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplements; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kidney; Kidney Diseases; Magnesium; Magnesium Deficiency; Magnesium Sulfate; Male; Middle Aged; Premedication; Retrospective Studies; Taxoids | 2017 |
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Etoposide; Female; Fluid Therapy; Gemcitabine; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2012 |